China slows controversial sickle cell gene therapy trials after patient deaths
New government restrictions in China have slowed investigator-initiated trials for sickle cell gene therapy following reports of recent patient deaths.
Regulatory changes halt fast testing routes
China previously allowed a fast and cheap route to human testing for biotech companies. Recent government restrictions have considerably slowed investigator-initiated trials in the country. These changes affect U.S. biotechs that wanted to bypass lengthy development timelines.
Safety concerns impact trial speed
News of recent patient deaths has contributed to the slowdown in these clinical studies. Investigators are now proceeding with considerably less speed than before the new rules. This shift impacts the broader landscape of human testing for gene therapies.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.